Evidence map›Paper›PMID 26753602›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2016

(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

C Sachpekidis, M Eder, K Kopka, W Mier, B A Hadaschik, U Haberkorn, A Dimitrakopoulou-Strauss

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Metaanalysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Pooled it
  3. Pooled it
  4. Mitigating bladder signal inEJNMMI physics · 2026
    Article
  5. Review
  6. Determining the optimal pharmacokinetic modelling and simplified quantification method of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  7. Combined whole-body dynamic and static PET/CT with low-dose [European journal of nuclear medicine and molecular imaging · 2024
    Article
  8. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [European journal of nuclear medicine and molecular imaging · 2024
    Article
  9. Comparison of parametric imaging and SUV imaging with [European journal of nuclear medicine and molecular imaging · 2024
    Article
  10. Direct Patlak Reconstruction of [International journal of molecular sciences · 2023
    Article
  11. Article
  12. Scientific reports · 2022
    Article
  13. Review
  14. Article
  15. Diagnostic Performance and Clinical Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  16. Article
  17. Pharmacokinetic studies of [European journal of nuclear medicine and molecular imaging · 2021
    Article
  18. Review
  19. Article
  20. European journal of nuclear medicine and molecular imaging · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C SachpekidisClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. christos_saxpe@yahoo.gr.
M EderDivision of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.
K KopkaDivision of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.
W MierDivision of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany.
B A HadaschikDepartment of Urology, University Hospital Heidelberg, Heidelberg, Germany.
U HaberkornClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.
A Dimitrakopoulou-StraussClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe aim to investigate the pharmacokinetics and distribution of the recently clinically introduced radioligand (68)Ga-PSMA-11 in men with recurrent prostate cancer (PC) by means of dynamic and whole-body PET/CT. The correlation between PSA levels and (68)Ga-PSMA-11 PET parameters is also investigated.

methods31 patients with biochemical failure after primary PC treatment with curative intent (median age 71.0 years) were enrolled in the analysis. The median PSA value was 2.0 ng/mL (range = 0.1 - 130.0 ng/mL) and the median Gleason score was 7 (range = 5 - 9). 8/31 (25.8 %) of the included patients had a PSA value < 0.5 ng/ml. All patients underwent dynamic PET/CT (dPET/CT) scanning (60 min) of the pelvis and lower abdomen as well as whole-body PET/CT with (68)Ga-PSMA-11. dPET/CT assessment was based on qualitative evaluation, SUV calculation, and quantitative analysis based on a two-tissue compartment model and a non-compartmental approach leading to the extraction of fractal dimension (FD).

results22/31 patients (71.0 %) were (68)Ga-PSMA-11-positive, while 9/31 (29.0 %) patients were (68)Ga-PSMA-11-negative. The median PSA value in the (68)Ga-PSMA-11-positive group was significantly higher (median = 2.35 ng/mL; range = 0.19 - 130.0 ng/mL) than in the (68)Ga-PSMA-11-negative group (median value: 0.34 ng/mL; range = 0.10 - 4.20 ng/mL). A total of 76 lesions were semi-quantitatively evaluated. PC recurrence-associated lesions demonstrated a mean SUVaverage = 12.4 (median = 9.0; range = 2.2 - 84.5) and mean SUVmax = 18.8 (median = 14.1; range = 3.1 - 120.3). Dynamic PET/CT studies of the pelvis revealed the following mean values for the PC recurrence-suspicious lesions: K1 = 0.26, k3 = 0.30, influx = 0.14 and FD = 1.24. Time-activity curves derived from PC-recurrence indicative lesions revealed an increasing (68)Ga-PSMA-11 accumulation during dynamic PET acquisition. Correlation analysis revealed a moderate, but significant, correlation between PSA levels and the number of lesions detected on (68)Ga-PSMA-11 PET/CT (r = 0.54) and between PSA levels and SUVaverage (r = 0.48) or SUVmax (r = 0.44).

conclusionsGa-PSMA-11 PET/CT demonstrated an overall detection rate of 71.0 % 60 min p.i. of the radiotracer in a mixed patient population with respect to PSA levels and including patients with very low PSA values. Higher PSA values were associated with a higher detection rate. The tracer uptake in PC-recurrence-indicative lesions is increasing during the 60 minutes of dynamic PET acquisition.

Indexed as

OligopeptidesPositron Emission Tomography Computed TomographyAgedAntigens, SurfaceEdetic AcidGallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedPelvisProstatic NeoplasmsRecurrenceWhole Body ImagingAntigens, SurfaceEdetic AcidFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIOligopeptides68Ga-PSMA-ligand PET/CTProstate cancer recurrenceProstate-specific membrane antigen (PSMA)PSATwo-tissue compartment model

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.